GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.20.
Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a report on Thursday, February 27th.
View Our Latest Stock Analysis on GeoVax Labs
Hedge Funds Weigh In On GeoVax Labs
GeoVax Labs Price Performance
NASDAQ:GOVX opened at $1.54 on Friday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The stock has a fifty day moving average of $1.85 and a 200 day moving average of $2.33.
About GeoVax Labs
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
See Also
- Five stocks we like better than GeoVax Labs
- How to Choose Top Rated Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Industrial Products Stocks Investing
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- High Flyers: 3 Natural Gas Stocks for March 2022
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.